Palvella Therapeutics (PVLA) Stock Price, News & Analysis

Company Overview

Palvella Therapeutics, Inc. (NASDAQ: PVLA) is a clinical‐stage biopharmaceutical company devoted to the discovery and development of innovative therapies for immunological and inflammatory diseases. The company employs a proprietary small‐molecule and biologics platform to identify and modulate key molecular pathways that drive neutrophil‐ and complement‐mediated inflammation, aiming to deliver targeted treatment options for patients with significant unmet medical needs.

Palvella’s pipeline comprises several preclinical assets designed to address both prevalent chronic inflammatory conditions and rare autoinflammatory syndromes. Utilizing its integrated chemistry and biology capabilities, the company seeks to optimize drug candidates for favorable pharmacokinetics, safety, and efficacy profiles. Palvella has also established strategic partnerships with academic institutions and industry collaborators to accelerate its research and development efforts.

Headquartered in the United States, Palvella Therapeutics operates a dedicated research and development center where its multidisciplinary team of experts in immunology, medicinal chemistry, and clinical sciences drives program advancement. Since its inception, the company has demonstrated a commitment to expanding its pipeline through both internal discovery and external collaborations, with the ultimate goal of bringing new treatment options to patients suffering from debilitating inflammatory diseases.

Key Stats

• Today's Range: $56.56 to $59.60
• 50-Day Range: $28.42 to $59.73
• 52-Week Range: $11.17 to $63.12
• Volume: 262,507 shs
• Average Volume: 127,118 shs
• Market Capitalization: $626.99 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $60.91
• Consensus Rating: Buy

Palvella Therapeutics Stock Analysis - MarketRank™

Palvella Therapeutics scored higher than 40% of companies evaluated by MarketBeat, and ranked 747th out of 946 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.1 / 5
• Analyst Rating: Buy

Consensus Rating

Palvella Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.08, and is based on 11 buy ratings, no hold ratings, and no sell ratings.

Upside/Downside

The consensus price target for Palvella Therapeutics is close to its current price, suggesting limited near-term upside or downside.

Amount of Analyst Coverage

Palvella Therapeutics has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Palvella Therapeutics are expected to grow in the coming year, from ($3.69) to ($2.77) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Palvella Therapeutics is -4.69, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Palvella Therapeutics is -4.69, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Palvella Therapeutics has a P/B Ratio of 10.16. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

10.50% of the float of Palvella Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Palvella Therapeutics has a short interest ratio ("days to cover") of 5.

Change versus previous month

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Palvella Therapeutics does not currently pay a dividend.

Dividend Growth

Palvella Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

10.50% of the float of Palvella Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Palvella Therapeutics has a short interest ratio ("days to cover") of 5.

Change versus previous month

News and Social Media

• Score: 3.0 / 5
• News Sentiment: 0.43

News Sentiment

Palvella Therapeutics has a news sentiment score of 0.43. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.71 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 8 news articles for Palvella Therapeutics this week, compared to 4 articles on an average week.

Search Interest

3 people have searched for PVLA on MarketBeat in the last 30 days. This is an increase of 200% compared to the previous 30 days.

MarketBeat Follows

2 people have added Palvella Therapeutics to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Palvella Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

20.50% of the stock of Palvella Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

40.11% of the stock of Palvella Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

PVLA Stock Analysis - Frequently Asked Questions

How have PVLA shares performed this year?

Palvella Therapeutics' stock was trading at $12.00 on January 1st, 2025. Since then, PVLA shares have increased by 372.4% and is now trading at $56.69.

How were Palvella Therapeutics' earnings last quarter?

Palvella Therapeutics, Inc. (NASDAQ:PVLA) posted its quarterly earnings data on Thursday, August, 14th. The company reported ($0.86) earnings per share for the quarter, missing the consensus estimate of ($0.78) by $0.08.
Read the conference call transcript.

Who are Palvella Therapeutics' major shareholders?

Top institutional investors of Palvella Therapeutics include Frazier Life Sciences Management L.P. (6.53%), Adams Street Partners LLC (2.70%), Geode Capital Management LLC (1.57%) and Clio Asset Management LLC (0.83%).
View institutional ownership trends.

How do I buy shares of Palvella Therapeutics?

Shares of PVLA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

• Last Earnings: 8/14/2025
• Today: 9/23/2025
• Next Earnings (Estimated): 11/12/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:PVLA
• Previous Symbol: NASDAQ:PVLA
• CIK: 1583648
• Web: www.pieris.com
• Phone: 857-246-8998
• Fax: 49-8161-141-1444
• Employees: N/A
• Year Founded: 2015

Price Target and Rating

• Average Price Target for Palvella Therapeutics: $60.91
• High Price Target: $90.00
• Low Price Target: $44.00
• Potential Upside/Downside: +7.4%
• Consensus Rating: Buy
• Rating Score (0-4): 3.08
• Research Coverage: 12 Analysts

Profitability

• EPS (Trailing Twelve Months): ($12.10)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$17.43 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -62.30%
• Return on Assets: -43.34%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 7.67
• Quick Ratio: 7.67

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $5.58 per share
• Price / Book: 10.16

Miscellaneous

• Outstanding Shares: 11,060,000
• Free Float: 8,793,000
• Market Cap: $626.99 million
• Optionable: N/A
• Beta: -0.04